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Abstract
Background: The objective of the study is to estimate the frequency of multimorbidity in type 2 diabetes patients
classified by health statuses in a European region and to determine the impact on pharmaceutical expenditure.
Methods: Cross-sectional study of the inhabitants of a southeastern European region with a population of
5,150,054, using data extracted from Electronic Health Records for 2012. 491,854 diabetic individuals were identified
and selected through clinical codes, Clinical Risk Groups and diabetes treatment and/or blood glucose reagent
strips. Patients with type 1 diabetes and gestational diabetes were excluded. All measurements were obtained at
individual level. The prevalence of common chronic diseases and co-occurrence of diseases was established using
factorial analysis.
Results: The estimated prevalence of diabetes was 9.6 %, with nearly 70 % of diabetic patients suffering from more
than two comorbidities. The most frequent of these was hypertension, which for the groups of patients in Clinical
Risk Groups (CRG) 6 and 7 was 84.3 % and 97.1 % respectively. Regarding age, elderly patients have more
probability of suffering complications than younger people. Moreover, women suffer complications more frequently
than men, except for retinopathy, which is more common in males. The highest use of insulins, oral antidiabetics
(OAD) and combinations was found in diabetic patients who also suffered cardiovascular disease and neoplasms.
The average cost for insulin was 153€ and that of OADs 306€. Regarding total pharmaceutical cost, the greatest
consumers were patients with comorbidities of respiratory illness and neoplasms, with respective average costs of
2,034.2€ and 1,886.9€.
Conclusions: Diabetes is characterized by the co-occurrence of other diseases, which has implications for disease
management and leads to a considerable increase in consumption of medicines for this pathology and, as such,
pharmaceutical expenditure.
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Background
Diabetes is regarded as an epidemic by The World Health
Organization (WHO) and is one of the non-contagious
chronic diseases with greatest socio-economic impact [1].
In Spain, the prevalence of diabetes is estimated to be
around 10 % [2]. Worldwide, diabetes-related health
expenditure accounted for 11 % of the total health
expenditure for 2011 [3].
Diabetes, like the majority of non-contagious chronic
diseases, is associated with multimorbitity, defined in the
growing literature as the existence of two or more
chronic conditions [4, 5]. Multimorbidity causes a nega-
tive impact on both clinical and health indicators and
primary health care costs [6, 7]. While true that the ana-
lysis of multimorbidity in this type of population is rela-
tively new, the tendency towards this approach to the
study of chronic diseases is ever increasing [8, 9].
This co-occurrence of diseases has implications from
a disease management point of view, as the features of
comorbid diseases can be much more complicated than
a simple aggregation of individual illnesses [10]. Previ-
ous studies have related diabetes to a set of diseases
such as cardiovascular, renal, obesity and the metabolic
syndrome [11–13].
In this research we use the Clinical Risk Groups
(CRG) patient grouping system to identify the diabetic
patient and the comorbidity [14–17] CRG is a relatively
new system that classifies individuals into mutually ex-
clusive categories, using medical contact or consult-
ation data. Each patient is assigned a severity level
according to his/her chronic health conditions. CRGs
classify the individual and all the medical services used
over a determined period of time. There are 1,079 basic
CRGs, all of which can be classified into the CRG core
health status that maintain clinical significance and take
into account future medical attention needs and the
clinical similarities of the individuals assigned to the
CRGs. The CRG core health status are: 1) healthy; 2) 4
significant acute disease; 3) single or multiple minor
chronic disease; 4) moderate chronic diseases; 5) dom-
inant chronic diseases; 6) Chronic disease in 2 or more
organ systems 7) multiple dominant chronic diseases;
8) metastatic malignancies; and 9) catastrophic condi-
tions. These basic groups can be aggregated into three
levels (ACRG) with each successive level maintaining
the health states and severity, while reducing the num-
ber of groups and, if necessary, adjusting the severity
level. This grouping system gives a morbidity popula-
tion pattern.
This study aims to estimate the most common
multimorbidities in patients with type 2 diabetes
(T2D) and their impact on pharmaceutical expend-




The objective of the study is to estimate the frequency
of multimorbidity in type 2 diabetes patients classified
by health statuses in a European region and to deter-
mine the impact on pharmaceutical expenditure.
Study population
The study was carried out in the Comunidad Valenciana
(CV) in eastern Spain, working with the population for
2012. The total resident population for that year was
5,150,054, from which information was taken on 491,854
patients diagnosed with diabetes, being treated with anti-
diabetics and/or blood glucose reagent strips. Patients
with juvenile diabetes, gestational diabetes and those not
receiving pharmacological treatment were excluded, re-
ducing the group to 350,015 patients.
Data
The study was a cross sectional observational study.
The data were obtained retrospectivity from the Elec-
tronic Health Record (EHR) and the Electronic Prescriber
system (GAIA) corresponding to patients attended during
the period January to December of 2012. Each patient
has a healthcare identification number in the Popula-
tion information System (PIS). Cases were identified
from the population morbidity database (SCP-cv) of
the Directorate General of Pharmacy of the Valencian
Community Government Health Department (Consel-
leria de Sanitat). The population was organized and
grouped using CRG. This model makes an initial classifica-
tion which groups International Classification of Disease,
9th revision, clinical modification (ICD-9-MC) diagnostic
codes in Major Diagnostic Categories (MDC). 350,015
people were selected as classified in MDC 101 Diabetes
Mellitus (DM) from the ICD-9-MC codes of 250.x0
assigned in their medical encounters in 2012 from a CV
total of 5,150,054.
Each MDC group’s different episode disease categories
(EDC) also made up from CIE-9-MC codes. It is considered
that EDC 427 Diabetes identifies patients with T1D and
EDC 424 Diabetes those with T2D. The chronic conditions
(EDCs) analyzed in the study as comorbid were: hyperten-
sion, dyslipidemia, mental disorders, osteoarticular disease,
cardiovascular and cerebrovascular disease (CVD), thyroid
disorders, severity obesity, osteoporosis, COPD, cancer,
renal disease, Alzheimer, asthma and pulmonary embolism.
CVD and Renal failure were included as comorbid still
being an event produced by diabetes complications how-
ever not being the only cause. For example, a patient diag-
nosed with diabetes would be in different levels of severity
according to comorbidities and complications. A patient
with diabetes but without any other associated chronic
pathology would be in status 5. Another patient with add
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on dominant chronic condition, such as hypertension,
would be in status 6.
To determine which comorbidities should be consid-
ered in this analysis, a review of previous literature was
conducted. In addition, we established a consensus with
specialists in internal medicine.
Other microvascular diabetes related complications were
identified from EHR using codes 205.x2 except for codes
250.10 and 250.12 (indicative of TD2 with ketoacidosis
and a condition close associate with T1D) similar to the al-
gorithm proposed by Kho et al. [18]. Nephropathy results
are not included here due to them having been insuffi-
ciently recorded.
Our algorithm was developed with primarily data ware-
house, easily accessed through Structured Query Language
(SQL).
Analysis
From the data obtained, we estimated the frequency of ep-
isodes of the chronic diseases in the cohort of patients
with T2D selected and classified in CRGs. To study the
prevalence of other chronic diseases, we adapt the meth-
odology previously reported by other authors [8]. Follow-
ing Barnet et al., we display frequencies, percentages and
cross tabulations for descriptive analysis. Furthermore, we
conduct a binary logistic regression to examine associa-
tions between physical and mental health comorbidities.
We further add a factorial analysis to study prevalence of
common chronic diseases and co-occurrence of diseases
and include CRG groups in the descriptive analysis.
An exploratory factor analysis was performed with a
varimax rotation applied with the aim of identifying the
multimorbidity clusters. Factor analysis is one of the most
widely used techniques in building models of multimor-
bidity [19, 20], although clinical criteria such as grouping
by affected organ systems are also pertinent [21, 22].
The EDCs were coded in binary format (i.e., 0 = no
disease and 1 = presence of the disease).
The factor analysis was based on a correlation matrix to
determine which diagnostic variables comprised each fac-
tor [19]. The factors obtained from this analysis were
interpreted as multimorbidity patterns. Pharmaceutical
use and expenditure were also analyzed bearing in mind
the resulting multimorbidity groups. Specifically, we ana-
lyzed the use of insulins, oral antidiabetics (OAD) – secre-
tegogues and non-secretegogues – and diabetes test strips,
as well as the average cost of these medicines and the total
primary health care pharmaceutical expenditure, taking
into account the multimorbidity factors obtained.
The incidence of diabetic related microvascular com-
plications (retinopathy, nephropathy and neuropathy)
were estimated grouped according to age and gender.
Logistic regression identified the effect of gender and
age groups (independent variables) on the coexistence of
such complications. Pearson chi 2 test was performed to
observe the differences between gender and we reported
P value under 0.05 were considered statistically significant.
The data used was analyzed using the statistics packet
SPSS version 20.0. To comply with the data protection law,
an anonymous and irreversibly dissociated number re-
placed the patient’s Healthcare Identification Number (PIS).
This observational study was also approved by the Behav-
ioural Research Ethics Board of the Generalitat Valenciana.
Results
Population description
Taking the total population of people diagnosed with
diabetes in the EHR, the estimated gross prevalence in
the CV for T2D is 9.6 %, with an average age of
67.4 years. 51.9 % of the population are male (Table 1).
Most of patients have diabetes-related comorbidities,
mainly hypertension (68 %) and comorbidities not re-
lated to diabetes (mental disorders: 25.05 %) (Table 1).
Regarding multimorbidity, 10 % of the diabetic patients
suffered from diabetes only, while 70 % suffered from
more than 2 comorbidities. The pharmaceutical expend-
iture shows a clearly rising trend corresponding to the in-
crease in comorbidities (Table 2).
Table 1 Number of people with comorbidities, average
pharmaceutical expenditure 2012
Variable Number Percent
Male 181,658 51.9 %
Female 168,357 48.1 %
Total 350,015 100 %
T2D Comorbidities related
Hypertension 239,611 68.46 %
Dyslipidemia 186,574 53.30 %
Severe obesity 27,270 7.79 %
T2D Comorbidities Unrelated
Mental disorders 87,673 25.05 %
Osteoarticular disease 85,920 24.55 %
Thyroid disorders 27,702 7.91 %
Osteoporosis 25,861 7.39 %
COPD 25,561 7.30 %
Cancer 22,792 6.51 %
Alzheimer 14,300 4.09 %
Asthma 11,120 3.18 %
Pulmonary embolism 964 0.28 %
Complications
Cardiovascular and cerebral disease 50,567 14.45 %
Renal failure 22,496 6.43 %
Retinopathy 25,594 7.31 %
Neuropathy 10,984 3.14 %
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Differentiating the population of diabetics according to
Core Health Status of CRG, it was observed that as the
health of the patient worsens, the prevalence of
comorbidities increases, in particular hypertension, dysli-
pidaemia and cardiovascular disease. Specifically, for
Health Statuses CRG 5 to 7 the prevalence of hyperten-
sion oscillates between 47.5 % - 97.1 %, while that of
dyslipidaemia ranges from 50.9 % to 59 %. For Health
Status CRG 8, the prevalence of cancer and hypertension
is notable, while for CRG 9 renal disease and hyperten-
sion are greater (Table 3).
Multimorbidity characteristics and pharmaceutical
expenditure
The factor analysis identifies 6 factors which explain
49.3 % of the variance. The Kaiser-Meyer-Olkin (KMO)
statistics value was 0.60 and Bartlett’s test of sphericity
was less than 5 %.
The resulting factors were: cardiovascular (hypertension,
dyslipidaemia, cardiovascular disease and renal disease),
osteoarticular (osteoporosis and osteoarticular disease),
mental (mental disorders and Alzheimer), respiratory
(asthma and COPD), metabolic (thyroid disorders and
obesity) and neoplasms (cancer and pulmonary embolism)
(Table 4).
Analyzing pharmaceutical use in diabetic patients ac-
cording to multimorbidity clusters, uniformity was ob-
served. Diabetic test strips is the most used technology
in diabetic patients. Secretagogue OADs are the most
used in patients with cardiovascular, osteoarticular and
metabolic factors (Table 5).
The highest average expenditure on insulin is for those
belonging to the metabolic factor, equivalent to 146.6 €.
The highest average expenditure on secretagogue OADs
corresponds to the osteoarticular factor, at 16.4€. For
nonsecretagogue OADs the highest expenditure was also
on patients in the metabolic factor, at 239.6 €. Patients
in the metabolic factor also had the highest average cost









Single 35,644 10.18 % 592.30 € 850.10 €
One additional 73,232 20.92 % 887.80 € 1,008.90 €
Two additional 94,618 27.03 % 1,189.60 € 1,076.60 €
Three additional 72,610 20.74 % 1,531.10 € 1,239.80 €
Four additional 41,505 11.86 % 1,881.60 € 1,371.00 €
Five additional 19,619 5.61 % 2,221.50 € 1,532.90 €
Six and more
additional
12787 3.65 % 3,825.41 € 1,802.90 €
Table 3 Prevalence of comorbidity and events in the diabetic population according to Core Health Status of CRG. 2012













(EDC) TOTAL % MALE FEMALE
T2D Comorbidities related
Hypertension 17,738 38.8 48,659 47.5 140,918 84.3 26,982 97.1 3,728 74.7 1,586 75.4 239,611 68.46 % 117,981 121,630
Dyslipidemia 16,402 35.9 52,082 50.9 97,985 58.7 16,490 59.4 2,473 49.5 1,142 54.3 186,574 53.30 % 96,982 89,592
Severe obesity 2,006 4.4 6,028 5.9 15,647 9.4 3,021 10.9 374 7.5 194 9.2 27,270 7.79 % 11,423 15,847
T2D Comorbidities Unrelated
Mental disorders 6,208 13.6 18,449 18 49,564 29.7 11,070 39.9 1,742 34.9 640 30.4 87,673 25.05 % 33,274 54,399
Osteoarticular
disease
5,610 12.3 18,972 18.5 50,860 30.4 8,957 32.2 1,151 23.1 370 17.6 85,920 24.55 % 29,324 56,596
Thyroid disorders 2,941 6.4 7,245 7.1 14,528 8.7 2,447 8.8 381 7.6 160 7.6 27,702 7.91 % 5,058 22,644
Osteoporosis 1,234 2.7 4,072 4 17,326 10.4 2,655 9.6 356 7.1 218 10.4 25,861 7.39 % 2,427 23,434
COPD 735 1.6 2,386 2.3 10,186 6.1 10,964 39.5 1,010 20.2 280 13.3 25,561 7.30 % 18,307 7,254
Cancer 688 1.5 2,382 23 12,652 7.6 2,159 7.8 4,667 93.5 244 11.6 22,792 6.51 % 13,639 9,153
Alzheimer 447 1 1,661 16 6,556 3.9 5,350 19.3 236 4.7 50 2.4 14,300 4.09 % 4,928 9,372
Asthma 661 1.4 1,590 16 6,932 4.1 1,717 6.2 151 3 69 3.3 11,120 3.18 % 3,381 7,739
Pulmonary
embolism




1,463 3.2 7,415 7.2 26,688 16 13,192 47.5 1,215 2.43 594 28.2 50,567 14.45 % 31,135 19,432
Renal disease 1,088 2.4 3,233 32 10,104 6 5,322 19.2 727 146 2,022 96.1 22,496 6.43 % 12,504 9,992
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in diabetic strips at 246.3 €. The group of patients in the
respiratory factor showed the highest average total
pharmaceutical expenditure of 2123.1€ (Table 5).
Analysis of diabetes microvascular complications
The prevalence of patients with T2D with microvascu-
lar complications with retinopathy (7.31 %), and neur-
opathy (3.64 %). Renal failure (6.43 %) and patients with
cardiovascular and cerebrovascular disease (14.45 %).
In the logistic regression the microvascular complica-
tions are related to the age and gender of the patients.
All the variables were significant. The reference is the
man of less than 40 years of age. From the logistic re-
gression we obtain some conclusions: regarding to
gender, women present lower probability than men of
suffering retinopathy, and more probability of suffering
the rest of the complications. Regarding age; older
patients, presents a higher probability of suffering all of
the complications mentioned (Table 6).
Discussion
In this study, both the prevalence of diabetes and the co-
morbidities are based on information from the EHR and
not from other sources usually used in cross sectional
studies. The use of the EHR for automated and subse-
quent analysis of patients with DM2 is not novel, and a
base of evidence is beginning to be built on this. Some
authors have published similar algorithms to our system
that allow automatic identification of diabetic patients.
Klompas et al. showed that using EHR data for auto-
mated diabetes surveillance was feasible and of great po-
tential utility. By taking advantage of the complete data
offered by EHRs, including laboratory test results and
prescriptions as well as diagnosis codes, an increase can
be achieved in both the sensitivity and detail of the
surveillance over the use of diagnosis codes alone. Using
an integrated algorithm, including laboratory, prescrip-
tion, and ICD-9 criteria, more patients with diabetes are
captured than when using any one criterion alone [23].
Regarding to the prevalence of patients who Suffered DM
microvascular complications: first, retinopathy (7.31 %),
Table 4 Factor analysis. Loading with values > ±0.3
Rotated Component Matrix
Variables Component
1 2 3 4 5 6
Hypertension .635
Dyslipidemia .596












Table 5 Frequency of medicine use and average pharmaceutical cost by multimorbidity groups











Insulins N (%) 6.8 % 6.5 % 7.8 % 8.2 % 7.5 % 8.3 %
Insulins Pharmaceutical expenditure (€) 122.4 118.1 133.5 139.9 146.6 125.6
(standard deviation) (307.1) (298.7) (314.3) (330.2) (361.5) (296.7)
Secretagogue OADs N (%) 32.9 % 32.5 % 31.7 % 30.5 % 32.8 % 30.9 %
Secretagogues Pharmaceutical expenditure (€) 16.0 16.4 15.3 14.5 14.7 15.2
(standard deviation) (24.0) (24.6) (23.2) (22.9) (22.0) (23.9)
Nonsecretagogue OADs N (%) 10.9 % 10.6 % 10.3 % 10.4 % 10.5 % 10.2 %
Non Pharmaceutical expenditure (€) 226.2 213.5 206.3 202.0 239.6 191.1
secretagogues (standard deviation) (362.6) (352.4) (349.3) (342.3) (415.3) (328.8)
Strips N (%) 31.5 % 31.8 % 33.9 % 31.7 % 32.5 % 37.0 %
Strips Pharmaceutical expenditure (€) 222.8 227.8 235.6 241.4 246.3 225.1
(standard deviation) (192.7) (192.8) (200.2) (203.4) (217.0) (191.5)
Average total cost Pharmaceutical expenditure (€) 1,441.0 1,645.5 1,816.7 2,123.1 1,540.6 1,968.9
(standard deviation) (1,290.4) (1,357.0) (1,570.6) (1,590.1) (1,421.9) (1,685.8)
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whose prevalence is very similar to that of other authors
(7.8 %) but far from the Pantalone et al. (3.4 %) [24]. The
second complication was the neuropathy (3.64 %) with a
prevalence above the indicated by Alonso Moran et al. [25]
(1.3 %) and below that of Pantalone (18 %). Finally, the
prevalence of nephropathy was also a lower figure (3.14 %)
to that of the Alonso Moran et al. (8 %) [26].
The main contribution of this study is the relation be-
tween diabetes co-morbidity and pharmaceutical expend-
iture. The relationship with the CRG patient classification
system, a clear trend in the increase of pharmaceutical
consumption was observed with the more serious health
states. In the case of the analyzed population, multimor-
bidity was present in nearly all cases, which is consistent
with the results of other studies [3, 16, 24, 27, 28] and
similar to that of Giralt [29].
Regarding the demographic profile of the population
(gender and age) findings were very similar to previous
studies [25]. In comparison with other studies, as the
age increases the likelihood of suffering complications
also increases [30].
The highest pharmaceutical cost implications are con-
nected to mental factors, being higher than that of other
factors such as cardiovascular, metabolic and the osteoar-
ticular. This is consistent with recent evidence indicating
that the presence of one or more mental comorbidities in
people with diabetes may increase the cost from 15 to
94 % [31].
The results were similar to those reported by Huber,
which is US $ 857 for diabetes alone, US $ 1,298 for the
presence of comorbidity, and US $ 1,795 for the pres-
ence of two comorbidities. The percentage of people
with comorbidities increases, two of those percentages
being similar to those reported by Huber [32].
As reported by Huber, the higher cost factor is of re-
spiratory. However, the cost found in this study is higher
than that estimated by Huber.
The main limitation regarding the estimates with using
this information system is the dependency placed on the
accurate recording of the patients’ data in the EHR by
the health professionals involved. Thus, the percentage
of DM remains more or less constant and requires
improvement in the recording of the codes.
Conclusions
Diabetes is characterized by the co-occurrence of other
diseases, which has implications from a disease manage-
ment point of view, and means a considerable increase
in pharmaceutical consumption for this pathology and,
as such, for pharmaceutical expenditure.
Additional studies are necessary for better characterization
of the development of the disease and multimorbidity
throughout life to establish intervention priorities.
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